Pertuzumab/Trastuzumab/Hyaluronidase-zzxf clinical trials
Also written RG6264 and RO7198574.
How each study uses Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Pertuzumab/Trastuzumab/Hyaluronidase-zzxf studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Jun 2020 · PHESGO · BLA 761170 (FDA, Drugs@FDA)
- European Union
- 21 Dec 2020 · Phesgo · EMEA/H/C/005386 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 6
Hoffmann-La Roche (4) · National Cancer Institute (NCI) (1) · Latin American Cooperative Oncology Group (1) · MedSIR (1) · Mayo Clinic (1) · Genentech, Inc. (1) · Dana-Farber Cancer Institute (1) · OHSU Knight Cancer Institute (1)
Often tested with
Tested in the same studies.
Pertuzumab (10) · Trastuzumab (7) · Ado-Trastuzumab Emtansine (3) · Paclitaxel (3) · Trastuzumab deruxtecan (2) · Entrectinib (2) · Inavolisib (2) · Alectinib (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, phase 3 first.
- Oct 2027Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaPhase 3 · National Cancer Institute (NCI)
- Apr 2027Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadePhase 2 · Latin American Cooperative Oncology Group
- Apr 2027PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerPhase 2 · MedSIR
Studies
Open first, then newest update. How each study uses Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as PH FDC SCHow we know
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Written as PhesgoHow we know
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT05256225Written as Hyaluronidase-zzxf/Pertuzumab/TrastuzumabHow we know
- Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeActive, not recruitingPhase 2Latin American Cooperative Oncology GroupNCT06068985Written as PHESGOHow we know
- Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Mayo ClinicNCT05730712Written as Hyaluronidase-zzxf/Pertuzumab/TrastuzumabHow we know
- PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerActive, not recruitingPhase 2MedSIRNCT06172127Written as Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML InjectionHow we know
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerCompletedPhase 3Hoffmann-La RocheNCT04024462Written as Pertuzumab and Trastuzumab FDC SCHow we know
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerCompletedPhase 3Hoffmann-La RocheNCT05415215Written as Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)How we know
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992Written as Pertuzumab, Trastuzumab, and Hyaluronidase-zzxfHow we know
- A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerCompletedPhase 3Hoffmann-La RocheNCT03493854Written as FDC of Pertuzumab and Trastuzumab SCHow we know
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnEarly Phase 1OHSU Knight Cancer InstituteNCT05238831Written as Hyaluronidase-zzxf/Pertuzumab/TrastuzumabHow we know
Given beside what is tested · 6 — Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is usual care or a partner of the new treatment
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239Written as PhesgoHow we know
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT05306041Written as PHESGOHow we know
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingPhase 2Baylor Breast Care CenterNCT05020860Written as Pertuzumab/Trastuzumab/Hyaluronidase-zzxfHow we know
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT05296798Written as PhesgoHow we know
- A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery SystemCompletedPhase 1Hoffmann-La RocheNCT05275010Written as Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)How we know
- A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast CancerCompletedPhase 2Hoffmann-La RocheNCT03674112Written as Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)How we know